IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

Periodontal Inflammation: Cellular Mechanisms And Clinical Implications

[1]Dr. Aaron F. Gomes, [2]Dr. Himanshu Noudiyal, [3]Dr. Rukhshana Khatoon, [4]Dr. Shivam Agarwal

[1]Professor and H.O.D., [2]JR III, [3]JR II, [4]JR II.

[1]Department of Periodontology and Oral Implantology,

[1]Uttaranchal Dental and Medical Research Institute, Dehradun, Uttarakhand, India

Abstract: Periodontal inflammation is a complex and dynamic immunobiological response to microbial challenge, central to the pathogenesis of periodontal diseases such as gingivitis and periodontitis. This review outlines the foundational aspects of periodontal inflammation, beginning with microbial etiology and host–pathogen interactions, and progressing through the clinical and histological features that mark disease evolution. A detailed account of the innate and adaptive immune responses underscores the roles of neutrophils, cytokines, and T cell subsets in driving either resolution or chronicity. Importantly, recent insights into pro-resolving mediators, such as resolvins and lipoxins, reveal inflammation resolution as an active process with substantial therapeutic potential. The review also explores emerging host-modulatory interventions, immune-engineered biomaterials, and microbiome-targeted therapies, positioning these advances within the broader movement toward precision periodontology. Collectively, the integration of molecular, cellular, and clinical perspectives offers a comprehensive foundation for understanding and managing periodontal inflammation.

Index Terms **-** periodontal inflammation, immune response, resolution mediators, host modulation therapy, microbiome, immune-engineering.

1. INTRODUCTION

Periodontal inflammation represents a fundamental host defence mechanism against microbial invasion in the oral cavity, particularly by pathogenic plaque biofilms that accumulate along the periodontal tissue. While initially protective, dysregulated or chronic inflammatory responses are central to the pathogenesis of periodontal diseases, notably gingivitis and periodontitis. This biologic process involves a complex interplay between bacterial virulence factors such as lipopolysaccharides from Gram-negative species and the host immune system, triggering a cascade of cellular and molecular events.[1]

Neutrophils, macrophages, and dendritic cells constitute the first line of defence, releasing a spectrum of pro-inflammatory cytokines and chemokines, including interleukin-1β (IL-1β), tumour necrosis factor-alpha (TNF-α), and prostaglandins. These mediators facilitate microbial clearance but also contribute to collateral tissue damage when persistent. Over time, if resolution mechanisms fail, the inflammation shifts from acute to chronic, leading to the destruction of periodontal connective tissue, alveolar bone resorption, and clinical attachment loss.[2]

Understanding the cellular mechanisms, molecular mediators, and resolution pathways of periodontal inflammation is essential not only for comprehending disease etiology but also for developing targeted interventions in regenerative periodontal therapy. Recent advances have highlighted the role of pro-resolving lipid mediators and host modulation strategies, suggesting a paradigm shift from purely antimicrobial approaches to therapies that also promote immune equilibrium.[3]

2. ETIOLOGY AND TRIGGERS OF PERIODONTAL INFLAMMATION

Periodontal inflammation arises from a multifactorial interplay between microbial, host, genetic, and environmental factors. The primary etiologic agent is the dental bacterial plaque biofilm, a structured polymicrobial community that adheres to the tooth surface and gingival margin. In health, this biofilm maintains a symbiotic relationship with the host. However, ecological shifts driven by poor oral hygiene, dietary changes, or systemic conditions can lead to dysbiosis, favouring pathogenic species.[4]

2.1 Microbial Dysbiosis and Keystone Pathogens

The transition from health to disease is marked by an increase in Gram-negative anaerobes, notably the "red complex" bacteria: *Porphyromonas gingivalis*, *Tannerella forsythia*, and *Treponema denticola*. *P. gingivalis*, in particular, is considered a keystone pathogen due to its ability to subvert host immune responses and reshape the microbial community without being numerically dominant.[5]

These pathogens release virulence factors such as lipopolysaccharides (LPS) (potent endotoxins that activate Toll-like receptors (TLRs), especially TLR4), gingipains (cysteine proteases that degrade host proteins and modulate cytokine activity) and fimbriae and hemagglutinins (facilitate adhesion and invasion of epithelial cells).[5]

2.2 Host Recognition and Immune Activation

The host detects microbial components via pattern recognition receptors (PRRs), including TLRs and NOD-like receptors (NLRs). This recognition triggers intracellular signalling cascades (e.g., NF-κB pathway), leading to the production of pro-inflammatory cytokines (IL-1β, TNF-α, IL-6) and matrix metalloproteinases (MMPs), particularly MMP-8 and MMP-9, which degrade extracellular matrix components. These mediators recruit neutrophils and monocytes to the site, initiating the innate immune response. While this response is essential for microbial clearance, persistent activation leads to collateral tissue damage.[6]

2.3 Modifying Risk Factors

Several host-related and environmental factors modulate the inflammatory response and disease susceptibility. Genetic predisposition like polymorphisms in IL-1 and TNF-α receptors influence cytokine expression and immune cell function. Systemic diseases such as diabetes mellitus enhances oxidative stress and impairs neutrophil function, exacerbating inflammation. Smoking alters neutrophil chemotaxis, reduces vascularity, and promotes a more pathogenic subgingival flora. Hormonal changes (puberty, pregnancy, and menopause) can amplify gingival inflammation via vascular and immune modulation. Psychosocial stress elevates cortisol levels, which may suppress immune surveillance and healing.[7]

2.4 Emerging Concepts

Recent studies suggest that metabolic byproducts of dysbiotic bacteria (e.g., short-chain fatty acids) and extracellular vesicles may further modulate host responses. Additionally, epigenetic modifications such as DNA methylation of inflammatory genes are being explored as potential contributors to disease susceptibility and chronicity.[8]

3. IMMUNOLOGICAL AND CELLULAR EVENTS IN PERIODONTAL INFLAMMATION

The host immune response to microbial biofilm accumulation initiates a cascade of tightly regulated cellular and molecular events. While this defence is aimed at neutralizing pathogens, its persistence fuelled by microbial virulence and host susceptibility drives periodontal tissue destruction.[9]

3.1 Innate Immune Response

The first line of defence involves the activation of epithelial cells, resident dendritic cells, and fibroblasts, which recognize pathogen-associated molecular patterns (PAMPs) via pattern recognition receptors (PRRs), particularly Toll-like receptors (TLRs). Among these, TLR2 and TLR4 are pivotal in recognizing lipopolysaccharides (LPS) and lipoproteins from Gram-negative bacteria.[10] This recognition activates intracellular signaling pathways predominantly the NF-κB and MAPK pathways leading to the transcription of inflammatory mediators such as Cytokines: IL-1β, TNF-α, IL-6, Adhesion molecules: ICAM-1, VCAM-1 and Prostaglandins and leukotrienes.[11-12]

These mediators recruit neutrophils to the sulcus, the dominant immune cells during early inflammation. Neutrophils engage in phagocytosis, degranulation, and NETosis, releasing reactive oxygen species (ROS), antimicrobial peptides, and matrix metalloproteinases (MMPs). However, prolonged neutrophil activation exacerbates collateral tissue damage.[11,13-14]

3.2 Transition to Adaptive Immunity

When microbial clearance fails, adaptive immunity is triggered. Antigen-presenting cells (APCs), such as Langerhans cells and dendritic cells, process microbial antigens and present them to T cells in regional lymph nodes. Differentiation of $CD4^+$ T helper (Th) cells into Th1, Th2, Th17, and Treg subtypes occur. Th1 cells promote macrophage activation via IFN-γ. Th17 cells secrete IL-17, enhancing neutrophil recruitment and contributing to bone loss. Treg cells suppress inflammation via IL-10 and TGF-β.[15-16]

Simultaneously, B lymphocytes and plasma cells accumulate in connective tissue, producing antibodies (IgG, IgA) against bacterial antigens. However, their hyperactivity may also sustain inflammation through immune complex formation and complement activation.[17]

3.3 Tissue Destruction and Feedback Loops

The chronic inflammatory state results in the release of MMPs, especially MMP-8 and MMP-9, along with cathepsins and serine proteases, degrading collagen and extracellular matrix proteins.[18-19] Osteoclastogenesis is promoted by the RANK–RANKL–OPG axis, contributing to alveolar bone resorption.[20] Recent evidence also underscores the role of innate lymphoid cells (ILCs) and epigenetic regulation (e.g., histone acetylation, DNA methylation) in fine-tuning inflammatory gene expression, introducing new layers of immunological complexity.[21]

4. CLINICAL AND HISTOLOGICAL FEATURES OF PERIODONTAL INFLAMMATION

Periodontal inflammation presents along a continuum from gingival health to periodontitis, each stage exhibiting distinct clinical signs and microscopic features.

4.1 Clinical Presentation

The clinical spectrum ranges from reversible inflammation confined to the gingiva (*gingivitis*) to irreversible destruction of supporting tissues (*periodontitis*). Gingival erythema and edema due to increased vascular permeability and vasodilation. Bleeding on probing (BOP) (indicator of active inflammation). Gingival enlargement or recession. Peridontal Pocket formation (result of junctional epithelium apical migration). Attachment loss and tooth mobility.[22-23]

4.2 Histological Hallmarks

Classic histopathological progression of inflammation in the gingiva was described by Page and Schroeder and includes four stages:[24]

Initial lesion (within 2–4 days)

Vasculitis beneath the junctional epithelium. Infiltration of polymorphonuclear leukocytes (PMNs)

Early lesion (4–7 days)

Dense lymphocytic infiltrate (mostly T cells). Collagen degradation begins

Clinical signs: erythema, bleeding

Established lesion (14–21 days)

Plasma cell predominance. Continued collagen loss

Clinical signs: Pocket formation

Advanced lesion (progression to periodontitis)

Extension into alveolar bone and periodontal ligament. Osteoclastic bone resorption

Clinical signs: Irreversible tissue destruction

These histological changes mirror immune activation and cytokine release, with escalating cellular infiltration, vascular proliferation, and connective tissue degradation as inflammation persists.[24]

5. RESOLUTION OF INFLAMMATION IN PERIODONTAL TISSUES

The resolution of inflammation is no longer regarded as a passive decline in immune activity but as an active, coordinated biological process essential for restoring tissue homeostasis after microbial clearance. In periodontal tissues, timely and effective resolution is critical to preventing the transition from protective inflammation to chronic, tissue-destructive disease.[25]

5.1 Key Cellular and Molecular Mechanisms

Once the initiating biofilm is disrupted or controlled, the inflammatory response enters a pro-resolving phase characterized by:

1. Neutrophil apoptosis: Programmed cell death that limits further release of tissue-damaging enzymes and reactive oxygen species (ROS).
2. Efferocytosis: Clearance of apoptotic neutrophils by macrophages, which subsequently shift from a pro-inflammatory M1 phenotype to a reparative M2 profile.
3. Recruitment of regulatory T cells (Tregs): These secrete immunomodulatory cytokines such as IL-10 and TGF-β, attenuating ongoing immune activity.[26]

At the molecular level, the transition is mediated by specialized pro-resolving mediators (SPMs), including Lipoxins (from arachidonic acid) Resolvins, Protectins and Maresins. These lipid-based mediators actively suppress neutrophil recruitment, enhance macrophage phagocytic function, and stimulate tissue repair and regeneration.[26-27]

5.2 Consequences of Failed Resolution

When resolution pathways are insufficient or delayed, the result is a state of unresolved chronic inflammation, characterized by continuous cytokine production (e.g., IL-1β, TNF-α), sustained recruitment of neutrophils and monocytes and excessive production of MMPs and osteoclast-activating signals (RANKL). This failure underlies the persistent tissue breakdown seen in periodontitis and amplifies systemic inflammatory burden.[28]

6. IMPLICATIONS FOR PERIODONTAL THERAPY

A deeper understanding of the immunological and molecular mechanisms underlying periodontal inflammation has significantly reshaped therapeutic approaches. Modern periodontal therapy now extends beyond mechanical debridement to include host modulation, immune-targeted interventions, and regenerative strategies aimed at restoring tissue homeostasis.[29]

6.1 Conventional Approaches and Their Limitations

Scaling and root planing (SRP) remains the cornerstone of non-surgical therapy, effectively reducing microbial load and inflammation. Surgical interventions (e.g., flap surgery, guided tissue regeneration) are employed in advanced cases to access deep pockets and promote regeneration. However, these approaches primarily address the bacterial etiology and may not fully resolve the underlying dysregulated host response, especially in systemically compromised individuals.[30-31]

6.2 Host Modulation Therapy (HMT)

Targeting the host response has emerged as a critical adjunct to conventional therapy. Sub-antimicrobial dose doxycycline (SDD) inhibits matrix metalloproteinases (MMPs), reducing collagen breakdown. Non-steroidal anti-inflammatory drugs (NSAIDs) temporarily suppress prostaglandin-mediated bone resorption, though long-term use is limited by systemic side effects. Omega-3 fatty acids enhance endogenous production of pro-resolving mediators like resolvins, supporting inflammation resolution.[29,32]

6.3 Emerging Biological and Immunomodulatory Therapies

Recent advances have introduced biomaterial-based immunotherapies and biological agents that modulate immune cell behavior: Macrophage polarization strategies in which biomaterials designed to shift macrophages from pro-inflammatory (M1) to pro-resolving (M2) phenotypes show promise in enhancing periodontal regeneration. Probiotic supplementation with beneficial bacteria (e.g., *Lactobacillus reuteri*) has demonstrated reductions in IL-1β, TNF-α, and clinical pocket depth, suggesting a role in rebalancing the oral microbiome. Bacteriophage and predatory bacteria therapies where novel antimicrobials selectively target pathogenic species without disrupting commensals, offering precision in microbial control.[33-34]

6.4 Personalized and Systemic Considerations

Systemic health (diabetes mellitus, cardiovascular disease) significantly influences periodontal outcomes. Integrating periodontal therapy with systemic disease management enhances both local and systemic inflammatory control.[35]

Precision periodontology guided by genetic, microbial, and immunological profiling may soon enable tailored interventions based on individual risk and response profiles.[36]

7. FUTURE PERSPECTIVES

The evolving understanding of periodontal inflammation has opened new frontiers in both diagnostics and therapeutics. As research continues to unravel the complex interplay between microbial dysbiosis, host immunity, and systemic health, several promising directions are emerging.

7.1 Precision Periodontology

Advancements in genomics, transcriptomics, and proteomics are paving the way for personalized periodontal care. By identifying individual risk profiles based on genetic polymorphisms, inflammatory biomarkers, and microbiome signatures clinicians may soon tailor interventions with greater specificity and predictability.[36]

7.2 Immuno-engineering and Biomaterials

The integration of immunomodulatory biomaterials into periodontal therapy is gaining momentum. Engineered scaffolds and hydrogels that promote macrophage polarization, Treg recruitment, or SPM release offer the potential to not only regenerate tissue but also actively resolve inflammation. These platforms may be combined with nanoparticles or controlled-release systems for targeted delivery of bioactive agents.[37]

7.3 Microbiome-Targeted Therapies

Beyond broad-spectrum antimicrobials, future strategies aim to reshape the oral microbiome using probiotics and prebiotics to restore microbial balance,[38] bacteriophage therapy for precision targeting of keystone pathogens[39] and CRISPR-based antimicrobials to selectively silence virulence genes.[40] These approaches promise to minimize collateral damage to commensal flora while enhancing ecological stability.

7.4 Digital and AI-Driven Diagnostics

Artificial intelligence and machine learning are being integrated into periodontal diagnostics enabling automated radiographic bone loss detection, predictive modelling of disease progression and real-time chairside risk assessment tools.[41]

7.5 Systemic Integration and Interdisciplinary Care

As the bidirectional links between periodontitis and systemic diseases (e.g., diabetes, cardiovascular disease, rheumatoid arthritis) become clearer, future care models will likely emphasize interdisciplinary collaboration. Periodontal health may serve as both a biomarker and modifiable risk factor in systemic disease management.[42]

8. CONCLUSION

Periodontal inflammation is a complex biological process that originates as a protective response to microbial biofilm but, when dysregulated, leads to progressive tissue destruction and systemic ramifications. From its microbial etiology and histopathological evolution to the intricate interplay of innate and adaptive immune responses, this review has outlined the foundational mechanisms that govern periodontal disease progression. Recent insights into the **active resolution of inflammation,** the emergence of **host-modulatory therapies,** and the integration of **biomaterial-driven immune-engineering** highlight a transformative shift in therapeutic paradigms. As the field moves toward personalized, mechanism-based care, harnessing these advancements will be key to improving long-term clinical outcomes and preserving oral-systemic health. A comprehensive understanding of these immunoinflammatory dynamics not only enhances diagnostic and therapeutic precision but also opens new opportunities for regenerative innovation and interdisciplinary collaboration.

REFERENCES

1. Silva N, Abusleme L, Bravo D, Dutzan N, Garcia-Sesnich J, Vernal R, Hernández M, Gamonal J. Host response mechanisms in periodontal diseases. J Appl Oral Sci. 2015 May-Jun;23(3):329-55. doi: 10.1590/1678-775720140259. PMID: 26221929; PMCID: PMC4510669.
2. Patel AA, Ginhoux F, Yona S. Monocytes, macrophages, dendritic cells and neutrophils: an update on lifespan kinetics in health and disease. Immunology. 2021 Jul;163(3):250-261. doi: 10.1111/imm.13320. Epub 2021 Mar 15. PMID: 33555612; PMCID: PMC8207393.
3. Torres W, Pérez JL, Díaz MP, D'Marco L, Checa-Ros A, Carrasquero R, Angarita L, Gómez Y, Chacín M, Ramírez P, Villasmil N, Durán-Agüero S, Cano C, Bermúdez V. The Role of Specialized Pro-Resolving Lipid Mediators in Inflammation-Induced Carcinogenesis. Int J Mol Sci. 2023 Aug 10;24(16):12623. doi: 10.3390/ijms241612623. PMID: 37628804; PMCID: PMC10454572.
4. Zhang S, Yu N, Arce RM. Periodontal inflammation: Integrating genes and dysbiosis. *Periodontol 2000*. 2019;82(1):129–142.

5. How KY, Song KP, Chan KG. Porphyromonas gingivalis: An Overview of Periodontopathic Pathogen below the Gum Line. Front Microbiol. 2016 Feb 9;7:53. doi: 10.3389/fmicb.2016.00053. PMID: 26903954; PMCID: PMC4746253.
6. Suresh R, Mosser DM. Pattern recognition receptors in innate immunity, host defense, and immunopathology. Adv Physiol Educ. 2013 Dec;37(4):284-91. doi: 10.1152/advan.00058.2013. PMID: 24292903; PMCID: PMC4089092.
7. Smyth MJ, Wherry EJ, Turk MJ. Innate immune recognition of cancer. *Cell*. 2016;164(6):1237–1251.
8. Łasica A, Golec P, Laskus A, Zalewska M, Gędaj M, Popowska M. Periodontitis: etiology, conventional treatments, and emerging bacteriophage and predatory bacteria therapies. *Front Microbiol*. 2024;15:1469414. doi:10.3389/fmicb.2024.1469414
9. Rather MA, Gupta K, Mandal M. Microbial biofilm: formation, architecture, antibiotic resistance, and control strategies. Braz J Microbiol. 2021 Dec;52(4):1701-1718. doi: 10.1007/s42770-021-00624-x. Epub 2021 Sep 23. PMID: 34558029; PMCID: PMC8578483.
10. Günther J, Seyfert HM. The first line of defence: insights into mechanisms and relevance of phagocytosis in epithelial cells. Semin Immunopathol. 2018 Nov;40(6):555-565. doi: 10.1007/s00281-018-0701-1. Epub 2018 Sep 4. PMID: 30182191; PMCID: PMC6223882.
11. Liu T, Zhang L, Joo D, Sun SC. NF-κB signaling in inflammation. Signal Transduct Target Ther. 2017;2:17023.
12. Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, Li Y, Wang X, Zhao L. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget. 2017 Dec 14;9(6):7204-7218. doi: 10.18632/oncotarget.23208. PMID: 29467962; PMCID: PMC5805548.
13. Lehman HK, Segal BH. The role of neutrophils in host defense and disease. J Allergy Clin Immunol. 2020 Jun;145(6):1535-1544. doi: 10.1016/j.jaci.2020.02.038. Epub 2020 Apr 10. PMID: 32283205; PMCID: PMC8912989.
14. Soehnlein O, Steffens S, Hidalgo A, Weber C. Neutrophils as protagonists and targets in chronic inflammation. Nat Rev Immunol. 2017;17(4):248–261.
15. Hilligan KL, Ronchese F. Antigen presentation by dendritic cells and their instruction of CD4+ T helper cell responses. Cell Mol Immunol. 2020 Jun;17(6):587-599. doi: 10.1038/s41423-020-0465-0. Epub 2020 May 20. PMID: 32433540; PMCID: PMC7264306.
16. Janeway CA Jr, Travers P, Walport M, et al. Immunobiology: The Immune System in Health and Disease. 5th edition. New York: Garland Science; 2001. The course of the adaptive response to infection. Available from: https://www.ncbi.nlm.nih.gov/books/NBK27125/
17. Cyster JG, Allen CDC. B Cell Responses: Cell Interaction Dynamics and Decisions. Cell. 2019 Apr 18;177(3):524-540. doi: 10.1016/j.cell.2019.03.016. PMID: 31002794; PMCID: PMC6538279.
18. Mukherjee A, Das B. The role of inflammatory mediators and matrix metalloproteinases (MMPs) in the progression of osteoarthritis. Biomater Biosyst. 2024 Feb 21;13:100090. doi: 10.1016/j.bbiosy.2024.100090. PMID: 38440290; PMCID: PMC10910010.
19. Lee HS, Kim WJ. The Role of Matrix Metalloproteinase in Inflammation with a Focus on Infectious Diseases. Int J Mol Sci. 2022 Sep 11;23(18):10546. doi: 10.3390/ijms231810546. PMID: 36142454; PMCID: PMC9500641.
20. Udagawa N, Koide M, Nakamura M, Nakamichi Y, Yamashita T, Uehara S, Kobayashi Y, Furuya Y, Yasuda H, Fukuda C, Tsuda E. Osteoclast differentiation by RANKL and OPG signaling pathways. J Bone Miner Metab. 2021 Jan;39(1):19-26. doi: 10.1007/s00774-020-01162-6. Epub 2020 Oct 20. PMID: 33079279.
21. Sun H, Qiu J, Qiu J. Epigenetic regulation of innate lymphoid cells. Eur J Immunol. 2024 Sep;54(9):e2350379. doi: 10.1002/eji.202350379. Epub 2024 Jun 2. PMID: 38824666.
22. Rathee M, Jain P. Gingivitis. [Updated 2023 Mar 27]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557422/
23. Mehrotra N, Singh S. Periodontitis. [Updated 2023 May 1]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK541126
24. Hajishengallis G, Korostoff JM. Revisiting the Page & Schroeder model: the good, the bad and the unknowns in the periodontal host response 40 years later. Periodontol 2000. 2017 Oct;75(1):116-151. doi: 10.1111/prd.12181. PMID: 28758305; PMCID: PMC5539911.
25. Barnig C, Bezema T, Calder PC, Charloux A, Frossard N, Garssen J, Haworth O, Dilevskaya K, Levi-Schaffer F, Lonsdorfer E, Wauben M, Kraneveld AD, Te Velde AA. Activation of Resolution Pathways to Prevent and Fight Chronic Inflammation: Lessons From Asthma and Inflammatory Bowel

Disease. Front Immunol. 2019 Jul 23;10:1699. doi: 10.3389/fimmu.2019.01699. PMID: 31396220; PMCID: PMC6664683.
26. Ortega-Gómez A, Perretti M, Soehnlein O. Resolution of inflammation: an integrated view. EMBO Mol Med. 2013 May;5(5):661-74. doi: 10.1002/emmm.201202382. Epub 2013 Apr 17. PMID: 23592557; PMCID: PMC3662311.
27. Ferreira I, Falcato F, Bandarra N, Rauter AP. Resolvins, Protectins, and Maresins: DHA-Derived Specialized Pro-Resolving Mediators, Biosynthetic Pathways, Synthetic Approaches, and Their Role in Inflammation. Molecules. 2022 Mar 3;27(5):1677. doi: 10.3390/molecules27051677. PMID: 35268778; PMCID: PMC8912121.
28. Sugimoto MA, Sousa LP, Pinho V, Perretti M, Teixeira MM. Resolution of Inflammation: What Controls Its Onset? Front Immunol. 2016 Apr 26;7:160. doi: 10.3389/fimmu.2016.00160. PMID: 27199985; PMCID: PMC4845539.
29. Balta MG, Papathanasiou E, Blix IJ, Van Dyke TE. Host Modulation and Treatment of Periodontal Disease. J Dent Res. 2021 Jul;100(8):798-809. doi: 10.1177/0022034521995157. Epub 2021 Mar 3. PMID: 33655803; PMCID: PMC8261853.
30. Bhansali RS. Non-surgical periodontal therapy: An update on current evidence. *World J Stomatol*. 2014;3(4):38–51.
31. Heitz-Mayfield LJ, Lang NP. Surgical and nonsurgical periodontal therapy. Learned and unlearned concepts. Periodontol 2000. 2013 Jun;62(1):218-31. doi: 10.1111/prd.12008. PMID: 23574468.
32. Golub LM, Lee HM. Periodontal therapeutics: Current host-modulation agents and future directions. Periodontol 2000. 2020 Feb;82(1):186-204. doi: 10.1111/prd.12315. PMID: 31850625; PMCID: PMC6973248.
33. Xue Y, Che J, Ji X, Li Y, Xie J, Chen X. Recent advances in biomaterial-boosted adoptive cell therapy. Chem Soc Rev. 2022 Mar 7;51(5):1766-1794. doi: 10.1039/d1cs00786f. PMID: 35170589.
34. Park JE, Kim DH. Advanced immunomodulatory biomaterials for therapeutic applications. *Adv Healthc Mater*. 2024;13(10):e2304496. doi:10.1002/adhm.20230449.
35. Sangalli L, Banday F, Sullivan A, Anjum K. Systemic Factors Affecting Prognosis and Outcomes in Periodontal Disease. Dent Clin North Am. 2024 Oct;68(4):571-602. doi: 10.1016/j.cden.2024.05.001. Epub 2024 Jun 29. PMID: 39244245.
36. Gundelly M, Pusuluri SV, Koduganti RR, Ambati M, Chiluveru S, Chandaka M. Precision Medicine in Periodontics: A Literature Review. Cureus. 2024 Sep 8;16(9):e68952. doi: 10.7759/cureus.68952. PMID: 39385855; PMCID: PMC11461172.
37. Green JJ. Immunoengineering has arrived. J Biomed Mater Res A. 2021 Apr;109(4):397-403. doi: 10.1002/jbm.a.37041. Epub 2020 Aug 4. PMID: 32588490; PMCID: PMC8112191.
38. Doucette H, Ward R, Wheeldon C, Whelan A. The impact of prebiotics and probiotics on the oral microbiome of individuals with periodontal disease: a scoping review. Can J Dent Hyg. 2024 Oct 1;58(3):182-195. PMID: 39513100; PMCID: PMC11539943.
39. Strathdee SA, Hatfull GF, Mutalik VK, Schooley RT. Phage therapy: From biological mechanisms to future directions. Cell. 2023 Jan 5;186(1):17-31. doi: 10.1016/j.cell.2022.11.017. PMID: 36608652; PMCID: PMC9827498.
40. Palacios Araya D, Palmer KL, Duerkop BA. CRISPR-based antimicrobials to obstruct antibiotic-resistant and pathogenic bacteria. PLoS Pathog. 2021 Jul 8;17(7):e1009672. doi: 10.1371/journal.ppat.1009672. Erratum in: PLoS Pathog. 2021 Dec 13;17(12):e1010153. doi: 10.1371/journal.ppat.1010153. PMID: 34237097; PMCID: PMC8266055.
41. Scott J, Biancardi AM, Jones O, Andrew D. Artificial Intelligence in Periodontology: A Scoping Review. Dent J (Basel). 2023 Feb 8;11(2):43. doi: 10.3390/dj11020043. PMID: 36826188; PMCID: PMC9955396.
42. Kim J, Amar S. Periodontal disease and systemic conditions: a bidirectional relationship. Odontology. 2006 Sep;94(1):10-21. doi: 10.1007/s10266-006-0060-6. PMID: 16998613; PMCID: PMC2443711.